MET 融合和剪接变异是异柠檬酸脱氢酶突变型星形细胞瘤的一个强烈不良预后因素。
MET fusions and splicing variants is a strong adverse prognostic factor in astrocytoma, isocitrate dehydrogenase mutant.
机构信息
Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
出版信息
Brain Pathol. 2024 May;34(3):e13198. doi: 10.1111/bpa.13198. Epub 2023 Aug 2.
Abstract
Liu et al. describe the adverse prognostic role of MET fusions and splicing variants in astrocytoma, isocitrate dehydrogenase mutant. On this basis, MET fusions and splicing variants was suggested to be a biomarker for the diagnosis of high-grade astrocytoma, isocitrate dehydrogenase mutant.
摘要
刘等人描述了 MET 融合和剪接变异在星形细胞瘤、异柠檬酸脱氢酶突变体中的不良预后作用。在此基础上，MET 融合和剪接变异被建议作为高级别星形细胞瘤、异柠檬酸脱氢酶突变体的诊断标志物。
Zotero 插件